Patient Support

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

A new CMS demonstration launching July 1 will offer eligible Part D beneficiaries access to branded obesity drugs at a $50 copay. Here's what manufacturers, payers, and pharmacies need to know.

Cameron Olig explains how transparency and direct access models can help pharma close the gap between drug pricing, distribution and the patient.

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

Kieran Daly discusses how adherence programs can improve patient outcomes, support specialty pharmacy performance, and reduce healthcare costs.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Bill McElnea and Hinal Sharma discuss the evolving role of a specialty pharmacy.

Kieran Daly explains how adherence and proof of use strategies improve commercial outcomes and the patient experience in specialty pharma.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

Kim Plesnarski explains what the biggest inefficiencies are in specialty pharma partnerships.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.